Founder, Chairperson, Chief Executive Officer, and Director · UNITED THERAPEUTICS Corp (UTHR)

Martine Rothblatt

A named executive officer of UNITED THERAPEUTICS in every fiscal year CompBrief holds from FY2016 to FY2025. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$18,038,972

FY2024: $23,009,609

1st of 4 named executive officers at United Therapeutics by FY2025 total.

4 named officers on file for UNITED THERAPEUTICS, FY2025

See an example →

What this number hides

The filing gives the total. UNITED THERAPEUTICS’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 29, 2026 (DEF 14A). Insider transactions since that proxy, current to 2026-11-07.

Free

Get Martine Rothblatt’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Martine Rothblatt and every company like it: Velarion Intel, free for 3 days, no card →

Martine Rothblatt compensation by year

UNITED THERAPEUTICS Summary Compensation Table · all 9 fiscal years held
In US dollars, as UNITED THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019FY2021FY2022FY2023FY2024FY2025
Salary$1,226,949$1,163,707$1,208,447$1,218,038$1,367,858$1,402,290$1,476,379$1,512,401$1,545,005
Bonus$0$0$0$0$0$0$0$0$0
Stock awards$0$0$0$0$0$0$5,376,600$7,594,474$6,067,990
Option awards$12,583,891$33,122,078$12,796,803$40,010,000$0$0$5,926,252$8,020,141$6,075,804
Non-equity incentive$992,464$1,598,163$2,021,250$1,753,125$2,132,813$3,909,114$4,161,000$5,625,000$4,281,875
Pension and deferred compensation$611,425$1,239,653$0$2,643,874$0$0$0$245,393$55,898
All other$9,600$9,600$9,800$10,000$10,400$10,800$17,826$12,200$12,400
Total$15,424,329$37,133,201$16,036,300$45,635,037$3,511,071$5,322,204$16,958,057$23,009,609$18,038,972

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: UNITED THERAPEUTICS Corp DEF 14A filed April 29, 2026, accession 0001082554-26-000009, and prior-year filings. Open the filing on EDGAR.

How this page was built: the UNITED THERAPEUTICS Corp filed document, accession 0001082554-26-000009. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.

$15.4M
$37.1M
$16.0M
$45.6M
$3.5M
$5.3M
$17.0M
$23.0M
$18.0M
FY16
FY17
FY18
FY19
FY21
FY22
FY23
FY24
FY25
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
RSU48,315$23,541,484—
RSU37,080$18,067,230—
RSU32,499$15,835,138—
RSU29,625$14,434,781—
Option207,720—$217.50

Per the Outstanding Equity Awards at Fiscal Year-End table in UNITED THERAPEUTICS Corp's FY2025 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

1,815 Form 4 lines since the FY2025 proxy (filed April 29, 2026)
current to 2026-11-07 · updated nightly
DateTransactionPlanSharesPriceHeld after
2026-11-05Sale10b5-1720$565.32332,383
2026-11-05Sale10b5-1280$568.86331,485
2026-11-05Sale10b5-1320$562.51333,623
2026-11-05Sale10b5-1520$563.98333,103
2026-11-05Sale10b5-1462$566.59331,921
2026-11-05Sale10b5-1156$567.93331,765
2026-11-05Exercise or conversion10b5-19,500$117.76333,943
2026-11-05Sale10b5-1562$570.53330,923

The 8 most recent of 1,815 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

UNITED THERAPEUTICS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
Martine Rothblatt · this pageChairperson and Chief Executive Officer$18,038,972
Michael BenkowitzPresident and Chief Operating Officer$14,385,655
James EdgemondChief Financial Officer and Treasurer$8,348,367
Paul MahonExecutive Vice President and General Counsel$5,531,313

Board service

UNITED THERAPEUTICS board · FY2021–FY2025

How this board is paid

Company policy: UNITED THERAPEUTICS pays directors a $60,000 cash retainer and $400,000 in Stock Options or RSUs. As stated in UNITED THERAPEUTICS's FY2025 proxy.

The full UNITED THERAPEUTICS compensation record

free company brief

This page is one person within UNITED THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the UNITED THERAPEUTICS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order UNITED THERAPEUTICS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are UNITED THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order UTHR

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Martine Rothblatt's compensation dossier